Hans Norrgren

Hans Norrgren

Auto-generated profile, based on publicly available information

Hans Norrgren

Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2013 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SASoo Aleman
Soo Aleman
NRNogol Rahbin
Nogol Rahbin
OWOla Weiland
Ola Weiland
LDLoa Davidsdottir
Loa Davidsdottir
MHMagnus Hedenstierna
Magnus Hedenstierna
RHRolf Hultcrantz
Rolf Hultcrantz
Background. The long-term effect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellular carcinoma (HCC), liver complications, liver-related death, and overall death in hepatitis C virus (HCV)–infected patients with liver cirrhosis is not fully known. Methods. These risks were evaluated during long-term follow-up in 351 patients with HCV-related cirrhosis. One hundred ten patients with SVR, 193 with non-SVR, and 48 who were untreated were included in a multicenter cohort that was initiated in 2001 and prospectively followed up for a mean of 5.3 (SD, 2.8) years. Complementary follow-up data from national registries were used to minimize the loss of patients during follow-up. Results. Six patients with SVR developed HCC at 0.04, 0.64, 2.4, 7.4, 7.4, and 7.6 years, respectively, after achieving SVR. The incidences of HCC, any liver complication, liver-related death, and overall death per 100 person-years were significantly lower in SVR time with 1.0, 0.9, 0.7, and 1.9, compared to 2.3, 3.2, 3.0, and 4.1 in non-SVR and 4.0, 4.9, 4.5, and 5.1 in untreated time. The long-term consequences did not decline significantly after >3 years versus during the first 3 years of follow-up. Conclusions. The risk for HCC, liver decompensation, and death in patients with liver cirrhosis related to HCV was markedly reduced after SVR, but a long-term risk of developing HCC remains for up to 8 years. Cirrhotic patients with HCV who achieve SVR should therefore maintain long-term surveillance for HCC. Future studies aimed to better identify those with remaining long-term risk for HCC are needed.

27 November 2000 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SASören Andersson
Sören Andersson
HNHans Norrgren
Hans Norrgren
ZSZacarias da Silva
Zacarias da Silva
ABAntonio Biague
Antonio Biague
SBSana Bamba
Sana Bamba
JAJan Albert
Jan Albert
THE EPIDEMIOLOGICAL and biological characteristics of human immunodeficiency virus (HIV) 1 and HIV-2 exhibit major differences. Whereas HIV-2 is confined mainly to West Africa, HIV-1 is spread globally. Furthermore, the rates of disease progression and transmission are significantly lower in HIV-2 infection.1-4 The reasons for these important differences are not fully understood, but in 1993 De Kock and coworkers5 postulated that differences in viral load may be important. Quantification of HIV-1 plasma viral RNA levels has become widely used for monitoring patients and has been found to have a high prognostic value for clinical progression and response to antiretroviral treatment.6,7 Plasma HIV-1 levels reach a semi-equilibrium (set point, inflection point) after the initial burst of viral replication during primary infection, and this set point is the best available predictor of disease outcome. Commonly, the plasma HIV-1 RNA concentrations reach this lowest level 3 to 6 months after seroconversion and then slowly start to increase. The rate of this gradual increase is determined by the level of the set point.7-9 The information about HIV-2 viral load is limited, and no data on the set point of plasma HIV-2 RNA have been previously published. However, a study by Simon et al10 based on virus isolation and quantification of proviral DNA load in peripheral-blood mononuclear cells indicated that HIV-2–infected patients had significantly lower viral loads than HIV-1–infected patients at corresponding CD4+ T-cell levels. In contrast, a few other studies have shown that the levels of proviral HIV-2 DNA in peripheral-blood mononuclear cells are similar to those in comparable groups of HIV-1–infected individuals.11-13 Two recent studies provided data on plasma HIV-2 RNA levels.14,15 Using different in-house assays, both studies showed lower HIV-2 than HIV-1 plasma viral load in cross-sectional samples, but neither included seroincident cases tested early after seroconversion.

15 April 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNSalma Nowroozalizadeh
Salma Nowroozalizadeh
FMFredrik Månsson
Fredrik Månsson
ZSZacarias da Silva
Zacarias da Silva
JRJohanna Repits
Johanna Repits
BDBraima Dabo
Braima Dabo
MJMarianne Jansson
Marianne Jansson
Guillain-Barré syndrome (GBS) is the prototype of an immune-mediated peripheral nerve disorder with acute onset and a monophasic disease course [1–5]. Because p

19 July 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JEJoakim Esbjörnsson
Joakim Esbjörnsson
FMFredrik Månsson
Fredrik Månsson
AKAnders Kvist
Anders Kvist
PIPer-Erik Isberg
Per-Erik Isberg
SNSalma Nowroozalizadeh
Salma Nowroozalizadeh
PMPatrik Medstrand
Patrik Medstrand
Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood.

22 March 2010 in Retrovirology
Verified
Journal Article
Open access
PDF file
JEJoakim Esbjörnsson
Joakim Esbjörnsson
FMFredrik Månsson
Fredrik Månsson
WMWilma Martínez-Arias
Wilma Martínez-Arias
EVElzbieta Vincic
Elzbieta Vincic
ABAntonio J Biague
Antonio J Biague
PMPatrik Medstrand
Patrik Medstrand
HIV-1 is one of the fastest evolving pathogens, and is distinguished by geographic and genetic variants that have been classified into different subtypes and circulating recombinant forms (CRFs). Early in infection the primary coreceptor is CCR5, but during disease course CXCR4-using HIV-1 populations may emerge. This has been correlated with accelerated disease progression in HIV-1 subtype B. Basic knowledge of HIV-1 coreceptor tropism is important due to the recent introduction of coreceptor antagonists in antiretroviral therapy, and subtype-specific differences regarding how frequently HIV-1 CXCR4-using populations appear in late-stage disease need to be further investigated. To study how frequently CXCR4-using populations appear in late-stage disease among HIV-1 subtype A and CRF02_AG, we evaluated the accuracy of a recombinant virus phenotypic assay for these subtypes, and used it to determine the HIV-1 coreceptor tropism of plasma samples collected during late-stage disease in Guinea-Bissau. We also performed a genotypic analysis and investigated subtype-specific differences in the appearance of CXCR4 tropism late in disease.

1 December 1997 in AIDS
Verified
Journal Article
Closed access
SASören Andersson
Sören Andersson
ZSZacarias da Silva
Zacarias da Silva
HNHans Norrgren
Hans Norrgren
FDFrancisco Dias
Francisco Dias
GBGunnel Biberfeld
Gunnel Biberfeld
To identify cost-efficient alternative antibody testing strategies for screening, confirmation and discrimination of HIV-1 and HIV-2 infections, including rapid simple tests (RST) as well as enzyme-linked immunosorbent assays (ELISA), in a HIV-1 and HIV-2-prevalent area. Evaluation and comparison of anti-HIV-1/2 assays, adhering to the World Health Organization recommendations for alternative confirmatory strategies, using banked and prospectively collected specimens in Guinea-Bissau. A total of 1110 consecutive sera from Bissau were included in the first phase, of which 198 (17.8%) were HIV-seropositive: 52 (4.7%) HIV-1, 120 (10.8%) HIV-2, and 26 (2.3%) HIV-1/HIV-2 dually reactive. In addition, 95 selected HIV-positive specimens were included for study of sensitivity and cross-reactivity between HIV-1 and HIV-2. Western blot was used as a gold standard for confirming the reactivity of the specimens. All specimens were screened by two assays, Enzygnost ELISA and Capillus RST. Samples reactive by any of the screening assays were further tested by assays chosen for confirmation: UBI ELISA, Innotest ELISA, Recombigen RST, Multispot RST and Immunocomb RST. The confirmatory RST as well as Wellcozyme Recombinant HIV-1 ELISA, PEPTI-LAV and INNO-LIA were also used to study differentiation between HIV-1 and HIV-2. The sensitivities of all assays were 100%. The specificities of the screening assays at initial and repeated testing were 98.0 and 99.7%, respectively, for Enzygnost and 99.8 and 99.9%, respectively, for Capillus. The various combinations of two or three assays showed specificities of 99.2–100%. Several possible combinations of assays were identified where a specificity of 100% and good differentiation between HIV-1 and HIV-2 was achieved. Significant differences in the capacity to discriminate were noted; Immunocomb and PEPTI-LAV had the lowest number of dual-reactive results. A follow-up study of 1501 consecutive samples tested with the strategy chosen for routine use showed a sensitivity and specificity comparable to ELISA and Western blot. High sensitivities and specificities were obtained with various combinations of assays including RST as well as ELISA, and these procedures are well suited for field use in Africa. Serodiagnostic strategies for HIV can be based on RST alone and differentiation between HIV-1 and HIV-2 can be achieved as part of these strategies. Large differences in the capacity of individual assays to discriminate between HIV-1 and HIV-2 were observed.